Abstract. Colorectal cancer (CRC) may be classified according to the level of microsatellite instability exhibited by the tumor. The malignant transformation of normal colonic mucosae to carcinomas may be accelerated by the loss or inactivation of DNA mismatch repair (MMR) genes. The present study examined the expression of certain MMR proteins [namely, MutL homolog 1 (MLH1), MutS homolog 2 (MSH2), MutS homolog 6 (MSH6) and PMS1 homolog 2 (PMS2)] in patients with stage II and III sporadic CRC. The association between the expression of these proteins, and the clinicopathological characteristics of patients with CRC and their tumors, was investigated. MMR protein expression was examined using immunohistochemistry. MLH1, MSH2, MSH6 and PMS2 protein expression was detected in 78.4% (120/153), 75.2% (115/153), 44.4% (68/153) and 79.7% (122/153) of stage II and III sporadic CRCs, respectively. Additionally, the expression of MLH1 and MSH6 was revealed to be significantly higher in stage III tumors when compared with stage II tumors (P<0.05). MLH1 and MSH6 negative tumors were larger, poorly differentiated and exhibited extraserosal invasion with infrequent lymph node metastasis (P<0.05). Patients with defects in MLH2 and PMS2 also had large tumors that exhibited extraserosal invasion and infrequent lymph node metastasis (P<0.05). No statistically significant associations were observed between MLH1, MSH2, MSH6 or PMS2 protein expression and patient age, sex, tumor localization or angiolymphatic invasion status (P>0.05). From the present study, it was concluded that MMR protein expression status evaluation may increase the efficiency of MMR testing and be useful in improving the individualized approach to patient monitoring and therapy.
Introduction
Colorectal cancer (CRC) is a major global public health concern (1) . CRC is the second leading cause of cancer-associated mortality in developed countries, and the sixth to seventh leading cause of cancer-associated mortality in developing countries (2) . Comprehensive studies investigating CRC tumorigenesis have made significant progress in previous decades, elucidating the molecular mechanisms governing CRC initiation, development and progression (3) .
CRC arises through at least two distinct genetic pathways. One of these pathways involves chromosomal instability (CIN), and the other involves microsatellite instability (MSI) (4) . Although the majority of sporadic CRCs exhibit CIN, MSI is only observed in ~15% of all CRCs, and the majority of CRCs with a high frequency of MSI are sporadic (5) .
MSI indicates a defective DNA mismatch repair (MMR) system, which is why it is used as a molecular marker. MMR is one of the best understood molecular pathways involved in the pathogenesis of inherited and sporadic cancer. The MMR system serves a function in DNA homeostasis, and is involved in the repair of specific types of errors that occur during DNA replication in dividing somatic cells (6) . MSI has been defined as variable microsatellite sequence length caused by insertions or deletions that occur within a tumor, but not in the corresponding normal tissue, and MSI tumors are characterized by an accelerated accumulation of mutations due to a defective MMR system (7) .
W hen M M R is f u nct ion i ng nor m a l ly, MuS homolog 2 (MSH2) and MutS homolog 6 (MSH6) bind to form the hMutS-α heterodimer, which recognizes and binds to mismatched base pairs, and recruits the MutL homolog 1 (MLH1)/PMS1 homolog 2 (PMS2) hMutL-α heterodimer to repair them. MSH2 and MLH1 are required to stabilize MSH6 and PMS2, respectively, and the loss of either MSH2 or MLH1 results in the degradation of its binding partner (8) .
MMR-deficient tumors are typically identified via immunohistochemistry (IHC), which detects the loss of expression of one or more MMR proteins (including MLH1, MSH2, MSH6 and PMS2) and MSI testing to identify tumors with elevated MSI (MSI-H) (9) . Reduced DNA repair protein expression is associated with MSI; therefore, numerous laboratories routinely use IHC with a panel of antibodies (specific to MLH1, PMS2, MSH2 and MSH6) as surrogate MSI markers (10) . IHC has the advantage of being flexible, with the ability to target any tissue type (including frozen and fixed samples, irrespective of the fixative used) and is performed by clinical pathology laboratories as a routine diagnostic test for MSI in patient tissues (11) . Therefore, IHC detection of MMR proteins may be a faster, easier and cheaper method of CRC detection when compared with genetic analysis for MSI.
In the present study, IHC analysis of MLH1, MSH2, MSH6 and PMS2 protein expression was performed to evaluate the prognostic significance of MMR status in patients with a series of stage II and III sporadic CRC.
Materials and methods

Patients and tissues.
Tissue samples from 153 patients with primary sporadic colorectal adenocarcinoma who underwent curative resection at the Civil Aviation General Hospital (Beijing, China) were obtained from a prospectively collected database between January 2004 and December 2013. The protocol for the present study was approved by the Institutional Review Board of the Civil Aviation General Hospital, and written informed consent was obtained from all patients in accordance with institutional regulations. All patients included in the present study were diagnosed with stage II or stage III sporadic colorectal adenocarcinoma. None of the patients received prior therapy, including radiotherapy or chemotherapy. All hematoxylin and eosin-stained sections were reviewed for tissue quality, and the highest quality section from each specimen was selected. Following an independent review by two pathologists, all tissues were histologically confirmed to be CRC. Clinical data, including sex and age, were obtained by chart review. Patients with incomplete data were not included in the present study.
Clinicopathological characteristics and histopathological review of tumor samples. The cancer-specific data evaluated for each patient included the tumor stage at presentation, tumor grade, specific histology, tumor location, angiolymphatic invasion status and the number of positive lymph nodes. The stage of each tumor was coded according to the AJCC 6th edition TNM staging system (12) (Table I), as follows: T1, tumor invades submucosa; T2, tumor invades muscularis propria; T3, tumor invades through the muscularis propria into the subserosa, or into nonperitonealized pericolic tissues; T4, tumor directly invades other organs or structures, or perforates visceral peritoneum; N0, no regional lymph node metastasis; N1, metastasis to one to three regional lymph nodes; N2, metastasis to four or more regional lymph nodes; M0, no distant metastasis; and M1, distant metastasis.
IHC analysis of MLH1, MSH2, MSH6 and PMS2 protein expression. IHC analysis of MLH1, MSH2, MSH6 and PMS2 protein expression was performed using a streptavidin-peroxidase IHC kit according to the manufacturer's protocol (Fuzhou Maixin Biotechnology Co., Ltd., Fuzhou, China). IHC staining was performed using 4-µm thick, paraffin-embedded CRC tissue sections mounted on positively charged slides. Tissue sections were deparaffinized with xylene and rehydrated through a gradient alcohol series. Sections were subsequently immersed in 10 mmol/l citrate buffer, pH 6.0, and heated in an autoclave at 121˚C for 5 min for non-enzymatic antigen retrieval. Next, to block the endogenous peroxidase activity, dual endogenous enzyme by incubating the sections in 3% hydrogen peroxide (H 2 O 2 ; Fuzhou Maixin Biotech. Co., Ltd. Fuzhou, China) blocking solution was applied to tissue sections for 10 min at 37˚C. Primary mouse monoclonal antibodies against human MLH1 (MAB-0642), MSH2 (MAB-0291), MSH6 (MAB-0643) and PMS2 (MAB-0656; Fuzhou Maixin Biotechnology Co., Ltd.) were incubated with the tissue sections for 20 min at room temperature. Next, the slides were washed three times using 0.1 M phosphate-buffered saline (PBS; pH 7.4) and incubated with a biotinylated horseradish peroxidase conjugated Rabbit anti-mouse IgG secondary antibodies (working liquid; cat no., KIT9710) (Fuzhou Maixin Biotechnology Co., Ltd.) for 20 min at 37˚C. Slides were washed three times following incubation with the secondary antibody using 0.1 M PBS (pH 7.4). The IHC reaction was visualized by 5-10 min of diaminobenzidine chromogen staining and 5 min hematoxylin counterstaining at room temperature. Negative controls were performed by omission of the primary antibody. Fig. 1 revealed that MLH1, MSH2, MSH6 and PMS2 staining was localized to the cell nuclei. Tissues with positive nuclear staining in the tumor cells were scored as positive. Tissue specimens with a complete absence of nuclear staining were scored as negative. The sections were counterstained with hematoxylin for nuclear counterstaining and examined for the extent and intensity of nuclear staining in tumor cells under a 200x magnification light microscope by two independent observers in a blinded manner. Discordant scores were resolved by review and consensus agreement or use of a third observer. Non-neoplastic colonic tissues, stroma and infiltrating lymphocytes normally demonstrated positive nuclear staining; therefore, these tissues were used as internal positive controls.
Statistical analysis. The Kruskal-Wallis test was applied (differentiation, tumor size, invasive depth and lymph node metastasis which are 3 categories). Cross-table analysis employing χ² test, as appropriate, was used to analyze associations between MMR defects (identified by IHC) and sex, ages, type, angiolymphatic invasion characteristics. Potential variables were verified by multivariate analysis using binary logistic regression. P<0.05 was considered to indicate a I  T1 or T2  N0  M0  IIa  T3  N0  M0  IIb  T4  N0  M0  IIIa  T1 or T2  N1  M0  IIIb  T3 or T4  N1  M0  IIIc  Any T  N2  M0  IIId  Any T  N3  M0  IIIc  Any T  N4  M0  IV Any T Any N M1
T, tumor; N, lymph node; M, metastasis.
statistically significant difference for all analyses, and all calculations were performed using SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA).
Results
Patient demographics.
A total of 153 patients with CRC were included in the present study. Out of these, 51 patients were ≤50 years old. A further 102 were >50 years old. Patient age at diagnosis ranged between 23-84 years, with a mean age of 58 years. Out of the 153 patients included in the present study, 97 (63.0%) were males and 56 (37.0%) were females. (Table II) . Of the 153 tumors included in the present study, 120 (78.4%) were MSH2 negative expression was also associated with the invasive depth of tumors, and the differences in expression were statistically significant (χ 2 =6.824; P=0.033). MSH2 protein expression was observed in 9/11 (81.5%) intra muscularia, 89/112 (79.5%) intra subserosa and 17/30 (56.7%) extra subserosa tumors.
MSH2 -----------------------------------------------------------
MSH6 ---------------------------------------------------------
MSH2 expression was detected in 27/44 (61.4%) tumors without lymph node metastasis, 58/73 (79.5%) with one to three metastases and 30/36 (83.8%) with four or more lymph node metastases. These differences in expression were statistically significant (χ 2 =7.305; P=0.026). MSH6 expression was more common in well-differentiated tumors than in moderately or poorly differentiated tumors, and this difference was statistically significant (poor vs. moderately differentiated, P=0.145; poor vs. well differentiated, P=0.007). MSH6 expression was detected in 22/36 (61.1%) well differentiated, 29/64 (45.3%) moderately differentiated and 17/54 (32.1%) poorly differentiated tumors.
MSH6 expression was observed in 15/21 (71.4%) tumors <3 cm, 39/92 (42.4%) tumors between 3-5 cm and 14/40 (35.0%) tumors >5 cm. These differences were statistically significant (χ 2 =5.818; P=0.05). The frequency of MSH6 positive tumors significantly decreased with increasing invasive depth, and this difference in expression was revealed to be statistically significant (χ 2 =6.051, P=0.049). MSH6 expression was observed in 7/11 (63.6%) intra muscularia, 53/112 (47.3%) intra subserosa and 8/30 (26.7%) extra subserosa tumors.
MSH6 expression was detected in 13/44 (29.5%) tumors without lymph node metastasis, 34/73 (46.6%) of tumors with one to three metastases and 21/36 (58.3%) of tumors with Table VI . PMS2 protein expression and the clinicopathological characteristics of patients and their tumors. The frequency of PMS2 positive tumors was significantly lower in tumors, which had invaded out of the subserosa, compared with those that had not, and this difference was statistically significant (χ 2 =12.308; P=0.002). PMS2 expression was observed in 9/11 (81.8%) intra muscularia, 96/112 (85.7%) intra subserosa and 17/30 (56.7%) extra subserosa tumors.
PMS2 expression was observed in 29/44 (65.9%) tumors without lymph node metastasis, 61/73 (83.6%) tumors with one to three metastases and 32/36 (88.9%) tumors with four or more lymph node metastases. These differences were statistically significant (χ 2 =9.256; P=0.010).
Discussion
MSI was first reported in 1993, as the presence of thousands of somatic alterations in the length of DNA microsatellite repeats in sporadic and familial colorectal tumors (13) . MSI is the result of defects in the MMR system and the MSH2, MLH1, PMS2 and MSH6 genes (14) . The MMR system recognizes and corrects base-pair mismatches and small nucleotide (1-4 base pair) insertion or deletion mutations within the duplex DNA that arise from nucleotide misincorporation during DNA replication (15, 16) . A properly functioning MMR system is essential for the maintenance of genomic stability, and the mutation rates in tumor cells with MMR deficiencies are 100-to 1,000-fold higher than in normal cells (17) . Consequently, a malfunctioning MMR system leads to genome-wide instability.
Previous studies have identified that colorectal tumors with MSI accumulate mutations at microsatellite sequences in the coding regions of tumor progression genes (15) . MSI is detected in tumor tissue by examining a panel of five markers: BAT25, BAT26, D2S123, D5S346 and D17S250, known as the Bethesda markers. This method requires specific laboratory expertise and equipment, and is routinely used in clinical pathology laboratories (18) . It has been demonstrated that loss of MLH1, MSH2, PMS2 and MSH6 protein expression is associated with a defective MMR system. Therefore, IHC analysis of the expression of these markers may potentially be used to detect MSI tumors (19) .
In the present study, MLH1, MSH2, MSH6 and PMS2 expression was observed at 70. 7 In the present study, in tumors >5 cm, MLH1, MSH2, MSH6 and PMS2 expression was lower than the expression of these proteins observed in the tumors <5 cm. This result is in accordance with the results of several previous studies (20) . For example, Lanza et al (11) demonstrated that patients with MMR defective colorectal tumors were younger and had tumors that were localized in the right-colon. MMR defective colorectal tumors exhibited infrequent lymph node metastasis, were larger and were poorly differentiated or of mucinous histology. Additionally, patients with MMR colorectal tumors had distinct clinicopathological characteristics, including a lower risk of recurrence. In another study by Sinicrope et al (21) , the prevalence of a defective MMR system in stage II and III colon cancers was 15%, and the MMR phenotype was significantly associated with higher tumor stage, proximal site, poor or undifferentiated histology, female sex and older age.
In the present study, it was observed that the loss of MLH1, MSH2, MSH6 and PMS2 expression was associated with advanced tumors. The loss of MLH1 and MSH6 protein expression was significantly associated with large, poorly differentiated tumors characterized by extraserosal invasion and infrequent lymph node metastasis. Similarly, the loss of MLH2 and PMS2 protein expression was significantly associated with large tumors characterized by extraserosal invasion and infrequent lymph node metastasis. No significant associations between the loss of MLH1, MSH2, MSH6 or PMS2 expression and the age, sex, tumor location or angiolymphatic invasion of patients with CRC were observed.
Unlike patients with intact MMR, patients with MMR deficient colon cancers do not benefit from 5-fluorouracil-based adjuvant therapy (22) . Therefore, the identification of patients with MMR deficient tumors is critical for the selection of an appropriate and effective treatment strategy. The results of the present study may help improve patient outcomes by assisting the identification of patients who possess CRCs exhibiting defective MMR. The use of this information in clinical decision-making would represent an important step toward individualized cancer therapy.
